MARKET

BIVI

BIVI

BioVie
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.20
-0.93
-6.58%
Closed 17:47 05/06 EDT
OPEN
13.35
PREV CLOSE
14.13
HIGH
14.24
LOW
13.01
VOLUME
66.31K
TURNOVER
--
52 WEEK HIGH
46.10
52 WEEK LOW
3.510
MARKET CAP
183.69M
P/E (TTM)
-1.1261
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 4d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Benzinga · 04/29 16:49
PINS, CLOV, ENPH and PBI among midday movers
Gainers: Brooklyn ImmunoTherapeutics (BTX) +44%.Uxin (UXIN) +25%.Ashford Hospitality Trust (AHT) +24%.Boxlight (BOXL) +21%.ADMA Biologics (ADMA) +18%.Clover Health Investments (CLOV) +16%.Unitil (UTL) +15%.Pitney Bowes (PBI) +15%.ClearSign Technologies (CL...
Seekingalpha · 04/28 16:41
41 Stocks Moving In Wednesday's Mid-Day Session
Gainers Aurora Mobile Limited (NASDAQ: JG) shares climbed 21.3% to $4.27 after Oppenheimer initiated coverage on the stock with an Outperform rating and a price target of $6 per share.
Benzinga · 04/28 16:06
ADMA Biologics, Brooklyn ImmunoTherapeutics leads healthcare gainers; Protalix BioTherapeutics, Benitec Biopharma among major losers
Gainers: ADMA Biologics (ADMA) +25%, Brooklyn ImmunoTherapeutics (BTX) +23%, Clover Health Investments (CLOV) +15%, Neptune Wellness Solutions (NEPT) +12%, Akouos (AKUS) +11%.Losers: Protalix BioTherapeutics (PLX) -40%, Benitec Biopharma (BNTC) -25%, BioVi...
Seekingalpha · 04/28 15:01
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 04/28 12:20
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27)
Benzinga · 04/28 11:26
BioVie to Present at 2021 B. Riley Securities Neuroscience Conference
GlobeNewswire · 04/28 11:18
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BIVI. Analyze the recent business situations of BioVie through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BIVI stock price target is 47.00 with a high estimate of 47.00 and a low estimate of 47.00.
EPS
Institutional Holdings
Institutions: 10
Institutional Holdings: 229.25K
% Owned: 1.65%
Shares Outstanding: 13.92M
TypeInstitutionsShares
Increased
0
0
New
6
127.44K
Decreased
1
5.00K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.09%
Pharmaceuticals & Medical Research
-0.30%
Key Executives
Chairman/Director
Terren Peizer
President/Chief Executive Officer
Cuong Do
Chief Financial Officer/Secretary
J. Wendy Kim
Chief Operating Officer
Jonathan Adams
Chief Scientific Officer
Penelope Markham
Other
Patrick Yeramian
Director
Richard Berman
Director
Steven Gorlin
Director
Robert Hariri
Director
Rajah Menon
Director
Sigmund Rogich
Independent Director
Hari Kumar
Independent Director
James Lang
Independent Director
Michael Sherman
Independent Director
Mina Sooch
No Data
About BIVI
BioVie Inc clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company has developed a new drug candidate, BIV201 (continuous infusion terlipressin) and has completed a mid-stage Phase IIa clinical trial for treating ascites due to advanced liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The initial target for BIV201 therapy is refractory ascites, a serious complication of liver cirrhosis with an estimated 50% mortality rate within six to 12 months.

Webull offers kinds of BioVie Inc stock information, including NASDAQ:BIVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIVI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIVI stock methods without spending real money on the virtual paper trading platform.